Agenda topics include topicals, GLP-1 drugs, biologics, PPI and H2 blockers, and more.
Agenda topics include topicals, GLP-1 drugs, biologics, PPI and H2 blockers, and more.
Stakeholders can submit feedback on the research agenda through September 28th.
The proposal would incorporate the latest ACOEM Guideline for knee disorders, and a public hearing is scheduled for October 16th.
The meeting will take place September 24th, with agenda topics including provision of coverage, benefits for injury or death, and occupational diseases.
The proposed changes will have a 45-day public comment period for stakeholders to provide feedback.
Impacted drugs include physician-dispensed and repackaged drugs, topicals, compounds, and OTC medications.
Impacted items would include pharmacy and topical reimbursement, home health, prior authorization, and more.
Stakeholder feedback for the audit plan will be accepted until 5:00 PM CST on August 6th.
The meeting discussed issues that could affect pharmacy reimbursement, statutory provider definitions, and medical accessibility reporting.
Topics covered include a new AI innovation office, a remote interpreters program, and updates for rulemaking and audits.
The August 20th webinar will discuss the impact of PBM legislation on workers' compensation systems.
A public hearing will be held on September 14th. with written comments accepted until October 5th.
The Committee is focused on high-cost and high-utilization medications, including GLP-1s, PPIs, anticonvulsants, topical agents, and biologics.
Commenters asked the DWC to clarify the scope of pharmacy and pharmacist definitions and prior authorization requirements.
The Fourth Edition of the AMA Guidelines have been in use since 2000 and would be updated to the Six Edition, published 2025.
